<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:58:24Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10277057" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10277057</identifier>
        <datestamp>2023-06-19</datestamp>
        <setSpec>bmjo</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">BMJ Open</journal-id>
              <journal-id journal-id-type="iso-abbrev">BMJ Open</journal-id>
              <journal-id journal-id-type="hwp">bmjopen</journal-id>
              <journal-id journal-id-type="publisher-id">bmjopen</journal-id>
              <journal-title-group>
                <journal-title>BMJ Open</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2044-6055</issn>
              <publisher>
                <publisher-name>BMJ Publishing Group</publisher-name>
                <publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10277057</article-id>
              <article-id pub-id-type="pmcid">PMC10277057</article-id>
              <article-id pub-id-type="pmc-uid">10277057</article-id>
              <article-id pub-id-type="pmid">37316311</article-id>
              <article-id pub-id-type="pmid">37316311</article-id>
              <article-id pub-id-type="publisher-id">bmjopen-2023-072707</article-id>
              <article-id pub-id-type="doi">10.1136/bmjopen-2023-072707</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Smoking and Tobacco</subject>
                </subj-group>
                <subj-group subj-group-type="hwp-journal-coll">
                  <subject>1506</subject>
                  <subject>1734</subject>
                </subj-group>
                <series-title>Protocol</series-title>
              </article-categories>
              <title-group>
                <article-title>Exenatide as an adjunct to nicotine patch for smoking cessation and prevention of postcessation weight gain among treatment-seeking smokers with pre-diabetes and/or overweight: study protocol for a randomised, placebo-controlled clinical trial</article-title>
              </title-group>
              <contrib-group>
                <contrib id="author-65184938" contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-5639-8802</contrib-id>
                  <name>
                    <surname>Yammine</surname>
                    <given-names>Luba</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-105346771" contrib-type="author">
                  <name>
                    <surname>Verrico</surname>
                    <given-names>Christopher D</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">2</xref>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib id="author-72546799" contrib-type="author">
                  <name>
                    <surname>Versace</surname>
                    <given-names>Francesco</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">4</xref>
                </contrib>
                <contrib id="author-99720212" contrib-type="author">
                  <name>
                    <surname>Webber</surname>
                    <given-names>Heather E</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-86445845" contrib-type="author">
                  <name>
                    <surname>Suchting</surname>
                    <given-names>Robert</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-63054855" contrib-type="author">
                  <name>
                    <surname>Weaver</surname>
                    <given-names>Michael F</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-47332006" contrib-type="author">
                  <name>
                    <surname>Kosten</surname>
                    <given-names>Thomas R</given-names>
                  </name>
                  <xref rid="aff2" ref-type="aff">2</xref>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib id="author-105346777" contrib-type="author">
                  <name>
                    <surname>Alibhai</surname>
                    <given-names>Husein</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">5</xref>
                </contrib>
                <contrib id="author-44370692" contrib-type="author">
                  <name>
                    <surname>Cinciripini</surname>
                    <given-names>Paul M</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">4</xref>
                </contrib>
                <contrib id="author-73888668" contrib-type="author">
                  <name>
                    <surname>Lane</surname>
                    <given-names>Scott D</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
                <contrib id="author-84039293" contrib-type="author">
                  <name>
                    <surname>Schmitz</surname>
                    <given-names>Joy M</given-names>
                  </name>
                  <xref rid="aff1" ref-type="aff">1</xref>
                </contrib>
              </contrib-group>
              <aff id="aff1"><label>1</label><institution content-type="department">Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences</institution>, <institution specific-use="Ringgold_12340">The University of Texas Health Science Center at Houston</institution>, <addr-line content-type="city">Houston</addr-line>, <addr-line content-type="state">Texas</addr-line>, <country>USA</country></aff>
              <aff id="aff2"><label>2</label><institution content-type="department">Menninger Department of Psychiatry and Behavioral Sciences</institution>, <institution specific-use="Ringgold_3989">Baylor College of Medicine</institution>, <addr-line content-type="city">Houston</addr-line>, <addr-line content-type="state">Texas</addr-line>, <country>USA</country></aff>
              <aff id="aff3"><label>3</label><institution specific-use="Ringgold_20116">Michael E DeBakey VA Medical Center</institution>, <addr-line content-type="city">Houston</addr-line>, <addr-line content-type="state">Texas</addr-line>, <country>USA</country></aff>
              <aff id="aff4"><label>4</label><institution specific-use="Ringgold_4002">The University of Texas MD Anderson Cancer Center</institution>, <addr-line content-type="city">Houston</addr-line>, <addr-line content-type="state">Texas</addr-line>, <country>USA</country></aff>
              <aff id="aff5"><label>5</label><institution specific-use="Ringgold_14743">University of Houston</institution>, <addr-line content-type="city">Houston</addr-line>, <addr-line content-type="state">Texas</addr-line>, <country>USA</country></aff>
              <author-notes>
                <corresp><label>Correspondence to</label> Dr Luba Yammine; <email>Luba.Yammine@uth.tmc.edu</email></corresp>
              </author-notes>
              <pub-date pub-type="collection">
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>13</day>
                <month>6</month>
                <year>2023</year>
              </pub-date>
              <volume>13</volume>
              <issue>6</issue>
              <elocation-id>e072707</elocation-id>
              <history>
                <date date-type="received">
                  <day>15</day>
                  <month>2</month>
                  <year>2023</year>
                </date>
                <date date-type="accepted">
                  <day>10</day>
                  <month>5</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Â© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</copyright-statement>
                <copyright-year>2023</copyright-year>
                <ali:free_to_read/>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbynclicense" start_date="2023-06-13">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:Â <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p>
                </license>
              </permissions>
              <self-uri xlink:title="pdf" xlink:href="bmjopen-2023-072707.pdf"/>
              <self-uri content-type="reviewers-comments-pdf" xlink:href="bmjopen-2023-072707.reviewer_comments.pdf"/>
              <self-uri content-type="draft-revisions-pdf" xlink:href="bmjopen-2023-072707.draft_revisions.pdf"/>
              <abstract>
                <sec>
                  <title>Introduction</title>
                  <p>Obesity and smoking are the two leading causes of preventable death in the USA. Unfortunately, most smokers gain weight after quitting. Postcessation weight gain (PCWG) is frequently cited as one of the primary barriers to a quit attempt and a common cause of relapse. Further, excessive PCWG may contribute to the onset or progression of metabolic conditions, such as hyperglycaemia and obesity. The efficacy of the current treatments for smoking cessation is modest, and these treatments have no clinically meaningful impact on mitigating PCWG. Here, we outline a novel approach using glucagon-like peptide 1 receptor agonists (GLP-1RA), which have demonstrated efficacy in reducing both food and nicotine intake. This report describes the design of a double-blind, placebo-controlled, randomised clinical trial that evaluates the effects of the GLP-1RA exenatide as an adjunct to nicotine patches on smoking abstinence and PCWG.</p>
                </sec>
                <sec>
                  <title>Methods and analysis</title>
                  <p>The study will be conducted at two university-affiliated research sites in Houston, Texas, the UTHealth Center for Neurobehavioral Research on Addiction and Baylor College of Medicine Michael E. DeBakey VA Medical Centre. The sample will consist of 216 treatment-seeking smokers with pre-diabetes (haemoglobin A1c of 5.7%â6.4%) and/or overweight (body mass index of 25 kg/m<sup>2</sup> or above). Participants will be randomised (1:1) to receive subcutaneous injections of placebo or 2âmg exenatide, once weekly for 14 weeks. All participants will receive transdermal nicotine replacement therapy and brief smoking cessation counselling for 14 weeks. The primary outcomes are 4-week continuous abstinence and changes in body weight at the end of treatment. The secondary outcomes are (1) abstinence and changes in body weight at 12 weeks post end of treatment and (2) changes in neuroaffective responses to cigarette-related and food-related cues as measured by electroencephalogram.</p>
                </sec>
                <sec>
                  <title>Ethics and dissemination</title>
                  <p>The study has been approved by the UTHealth Committee for the Protection of Human Subjects (HSC-MS-21-0639) and Baylor College of Medicine Institutional Review Board (H-50543). All participants will sign informed consent. The study results will be disseminated via peer-reviewed publications and conference presentations.</p>
                </sec>
                <sec>
                  <title>Trial registration number</title>
                  <p><ext-link xlink:href="NCT05610800" ext-link-type="uri">NCT05610800</ext-link>.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>substance misuse</kwd>
                <kwd>obesity</kwd>
                <kwd>clinical trial</kwd>
              </kwd-group>
              <funding-group specific-use="FundRef">
                <award-group id="funding-1">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Institutes of Health, National Institute of Drug Abuse</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>1R01DA053241-01A1</award-id>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>special-feature</meta-name>
                  <meta-value>unlocked</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <boxed-text id="BX1" position="float">
              <caption>
                <title>STRENGTHS AND LIMITATIONS OF THIS STUDY</title>
              </caption>
              <list list-type="bullet">
                <list-item>
                  <p>This trial will examine the glucagon-like peptide 1 receptor as a novel target for smoking cessation and postcessation weight management.</p>
                </list-item>
                <list-item>
                  <p>This trial will use a randomised, double-blinded, placebo-controlled design with prespecified outcome measures and intention-to-treat analysis.</p>
                </list-item>
                <list-item>
                  <p>Building on our previous 6-week trial of exenatide, the current study will extend the treatment duration to 14 weeks and include a follow-up at 12 weeks post end of treatment.</p>
                </list-item>
                <list-item>
                  <p>By assessing neuroaffective responses to nicotine-related and food-related stimuli via electroencephalogram, the trial will provide a potential mechanism for the efficacy of exenatide in this population of smokers.</p>
                </list-item>
                <list-item>
                  <p>A potential limitation of the trial is the focus on smokers who are prediabetic and/or overweight, which may limit the generalisability of the findings.</p>
                </list-item>
              </list>
            </boxed-text>
            <sec sec-type="intro" id="s1">
              <title>Introduction</title>
              <p>Obesity remains a major public health crisis with widespread impact on healthcare costs, quality of life and mortality. US prevalence data indicate that the majority (i.e. 74%) of American adults are overweight/obese - a 10% increase from 2000. <xref rid="R1" ref-type="bibr">1</xref> The only risk factor currently surpassing obesity as the leading cause of preventable morbidity and mortality is cigarette smoking. Approximately 400â000 Americans die each year from smoking-related causes, and 16âmillion Americans live today with a smoking-related disease.<xref rid="R2" ref-type="bibr">2</xref></p>
              <p>Although the health benefits of achieving smoking abstinence are extensive, including reductions in cardiovascular disease, chronic obstructive pulmonary disease and cancer risks, approximately 80%â90% of those who quit smoking experience rapid and significant weight gain, which partially attenuates these benefits.<xref rid="R2" ref-type="bibr">2 3</xref> On average, former smokers gain 5â15 pounds of body weight within the first few months of quitting,<xref rid="R3" ref-type="bibr">3</xref> and a non-trivial proportion of quitters gain more than 20 pounds.<xref rid="R3" ref-type="bibr">3</xref> Postcessation weight gain (PCWG) is problematic for several reasons. First, concerns about PCWG prevent some people from initiating a quit attempt.<xref rid="R4" ref-type="bibr">4â6</xref> Second, PCWG can be a cause of relapse.<xref rid="R7" ref-type="bibr">7â9</xref> Third, PCWG can worsen metabolic health, leading to the development or progression of obesity and type 2 diabetes (T2D), potentially contributing to premature morbidity and mortality associated with these diseases.<xref rid="R10" ref-type="bibr">10â14</xref></p>
              <p>Glucagon like peptide-1 (GLP-1) is produced in intestinal L-cells and released from the gut in response to food intake.<xref rid="R15" ref-type="bibr">15â18</xref> By stimulating insulin secretion and inhibiting glucagon secretion, GLP-1 regulates postprandial glucose excursions. GLP-1 is also known to stimulate centrally mediated appetite control and satiety.<xref rid="R19" ref-type="bibr">19 20</xref> Notably, GLP-1 receptor agonists (GLP-1RA) are currently used for the treatment of T2D and weight management in people with and without T2D. GLP-1 receptors are expressed in many brain regions. In addition to the hypothalamus and brain stem, GLP-1 receptors are expressed throughout the mesolimbic dopamine system,<xref rid="R21" ref-type="bibr">21</xref> and GLP-1 containing neurons extend directly into the ventral tegmental area and nucleus accumbens.<xref rid="R22" ref-type="bibr">22</xref> These brain regions are intimately associated with the regulation of food-related and nicotine-related reward. Consistent with this, preclinical studies have shown that GLP-1RAs significantly decrease nicotine self-administration<xref rid="R23" ref-type="bibr">23</xref> and attenuate nicotine conditioned place preference.<xref rid="R24" ref-type="bibr">24</xref> Further, our recent clinical trial of a GLP-RA extended-release exenatide showed that in the sample of 82 smokers who were prediabetic and/or overweight, 6 weeks treatment with exenatide resulted in a higher probability of abstinence and a lower probability of PCWG, compared with placebo.<xref rid="R25" ref-type="bibr">25</xref> The objective of the current phase II clinical trial is to extend these promising findings by: (1) investigating the robustness of exenatideâs effects following a longer treatment and post-treatment period and (2) exploring putative mechanisms through which exenatide might facilitate smoking cessation and mitigate PCWG. Recent calls have been made for an experimental therapeutic approach to designing clinical trials in which the focus is not only on testing whether an intervention works but on gaining insight into how an intervention works through hypothesised target mechanisms.<xref rid="R26" ref-type="bibr">26</xref></p>
            </sec>
            <sec sec-type="methods" id="s2">
              <title>Methods and analysis</title>
              <sec id="s2-1">
                <title>Study design</title>
                <p>This clinical trial will use a randomised, double-blind, placebo-controlled design and will be conducted at two US sites, the University of Texas Health Science Center at Houston (UTHealth), Center for Neurobehavioral Research on Addiction (CNRA) and Michael E. DeBakey VA Medical Center (MEDVAMC). The sample will consist of 216 treatment-seeking adult smokers who have pre-diabetes and/or are overweight. Participants will be randomised (1:1) to receive exenatide, 2âmg or placebo (sterile saline, 0.9%), subcutaneously, once weekly for 14 weeks. All participants will receive nicotine replacement therapy (NRT, nicotine patches) for daily use and individual smoking cessation counselling. Participants will attend weekly clinic visits to receive exenatide/placebo and NRT and complete assessments of smoking frequency and quantity, breath carbon monoxide (CO) levels, weight and other assessments. Electroencephalogram (EEG) will be conducted at baseline and before the quit attempt to assess neuroaffective responses to food, nicotine and emotional stimuli. Primary outcomes (end-of-treatment abstinence and weight change) will be assessed at 12 weeks post-target quit day. Participants will return for a follow-up visit 12 weeks after the end of treatment (24 weeks post-target quit day) for the assessment of weight and smoking status.</p>
              </sec>
              <sec id="s2-2">
                <title>Study aims</title>
                <sec id="s2-2-1">
                  <title>Specific aims</title>
                  <p>Aim 1: To determine if exenatide improves end-of-treatment smoking abstinence rates.</p>
                  <p>Hypothesis 1: Compared with placebo, treatment with exenatide will result in a higher rate of 4-week continuous abstinence (self-reported and biochemically verified by expired breath CO levels) at 12 weeks post-target quit day.</p>
                  <p>Aim 2: To determine if exenatide mitigates PCWG.</p>
                  <p>Hypothesis 2: Compared with placebo, treatment with exenatide will be associated with reduced PCWG at 12 weeks post-target quit day.</p>
                </sec>
                <sec id="s2-2-2">
                  <title>Exploratory aims</title>
                  <p>Aim 3: To assess the effect of exenatide on post-treatment abstinence and weight.</p>
                  <p>Hypothesis 3a: Compared with placebo, treatment with exenatide will result in a higher rate of 4-week continuous abstinence (self-reported and biochemically verified) at 24 weeks post-target quit day.</p>
                  <p>Hypothesis 3b: Compared with placebo, treatment with exenatide will be associated with lower PCWG at 24 weeks post-target quit day.</p>
                  <p>Aim 4: To explore the effect of exenatide on neuroaffective responses to food-related, nicotine-related and emotional stimuli.</p>
                  <p>Hypothesis 4: Treatment with exenatide will be associated with an attenuation of event-related potential (ERP) reactivity specific to nicotine-related and food-related stimuli at week 3, relative to baseline ERP reactivity.</p>
                </sec>
              </sec>
              <sec id="s2-3">
                <title>Participants</title>
                <sec id="s2-3-1">
                  <title>Eligibility</title>
                  <p>Participants will be 216 males and females between ages 18 and 75 years who report smoking 5 or more cigarettes per day for at least the past year and state a desire to quit smoking (defined as âintend to quit within 1âmonthâ). Participants must have glycosylated haemoglobin (HbA1C) levels between 5.7% and 6.4% and/or a body mass index (BMI) of â¥25âkg/m<sup>2</sup>.</p>
                  <p>The following exclusion criteria will be applied: (1) personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2; (2) history of pancreatitis or risk of pancreatitis; (3) T1D or T2D mellitus; (4) severe cardiovascular disease (history of myocardial infarction, life-threatening arrhythmia or worsening angina pectoris); (5) severe gastrointestinal disease (ie, severe gastroparesis); (6) creatinine clearance &lt;45âmL/min or end-stage renal disease: (7) psychotic or bipolar disorder, or mood disorder with psychotic features, or eating disorder (existing diagnosis or as determined by the structured interview); (8) moderate to high risk of suicidality; (9) psychoactive substance abuse or dependence (excluding nicotine dependence) within the past 3 months; (10) current use of glucose lowering medications; smoking cessation medications, medications used for weight management, or medications known to impact weight; (11) current use of chewing tobacco, snuff, snus or electronic cigarettes; (12) previous medically adverse reaction to study medications or nicotine, (13) women who are currently pregnant or lactating, or of childbearing potential and are not using medically accepted forms of contraception and (14) any illness or condition which in the opinion of the principal investigator (PI) and/or the study physician would preclude safe and/or successful completion of the study.</p>
                </sec>
                <sec id="s2-3-2">
                  <title>Discontinuation/withdrawal criteria</title>
                  <p>The participant may be discontinued at any time during the study at the discretion of the PI and/or the study physician for safety, behavioural, compliance or administrative reasons. Efforts must be made to have the participants, who discontinue the study medication, to continue in the study. Only participants who withdraw consent will be considered as withdrawn from the study.</p>
                </sec>
              </sec>
              <sec id="s2-4">
                <title>Screening</title>
                <p>Participants will be recruited using various strategies, including flyers, posters, newspapers and companies that provide recruitment services for clinical research using online platforms. Potential participants will complete a brief telephone prescreen to determine initial eligibility. The prescreen assessment includes questions assessing medical and psychiatric history, psychoactive substance use and smoking history. Based on the initial prescreen, individuals who appear eligible will be invited for a face-to-face screening visit.</p>
                <p>The screening will begin with the completion of the informed consent (see <xref rid="SP1" ref-type="supplementary-material">online supplemental material</xref>) which will be obtained by the PI or designee. Informed consent procedures will include details of the study, potential risks, study timeline and voluntariness of participation and dropping out. Following informed consent, each participant will complete demographic, medical and smoking history assessments and undergo a psychiatric evaluation and physical examination. Blood samples will be collected to examine complete blood count (CBC), comprehensive metabolic panel (CMP), pancreatic enzymes and HbA1C levels. Urine samples will be collected to assess cotinine levels and to rule out drug use and pregnancy (in women of childbearing potential).</p>
                <supplementary-material id="SP1" position="float" content-type="local-data">
                  <object-id pub-id-type="doi">10.1136/bmjopen-2023-072707.supp1</object-id>
                  <label>Supplementary data</label>
                  <p>
                    <inline-supplementary-material id="SS1" xlink:href="bmjopen-2023-072707supp001.pdf" content-type="local-data"/>
                  </p>
                </supplementary-material>
              </sec>
              <sec id="s2-5">
                <title>Study visits</title>
                <p>After determining study eligibility, qualified participants will return to the clinic once a week for 14 treatment visits. Visits will include assessments of vital signs, adverse events (AEs) and concomitant medications; administration of exenatide/placebo and dispensation of nicotine patches for the upcoming week; smoking cessation counselling; and completion of various assessments as detailed in the Data collection and measures subsection and <xref rid="T1" ref-type="table">table 1</xref>.</p>
                <table-wrap position="float" id="T1">
                  <label>Table 1</label>
                  <caption>
                    <p>Study design and assessment schedule</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <thead>
                      <tr>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">Phase â</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">Screen</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="2">Run-in</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="13">Treatment period</td>
                        <td align="left" valign="bottom" rowspan="1" colspan="1">F/U</td>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>Week <italic toggle="yes">â</italic></td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â4 to â1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">8</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">9</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">10</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">11</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">12</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">13</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">14</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">15</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">26</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>Approximate day â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â28 to â7</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">8</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">15</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">22</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">29</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">36</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">43</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">50</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">57</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">64</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">71</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">77</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">84</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">91</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">99</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">183</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>Visit <italic toggle="yes">â</italic></td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">8</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">9</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">10</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">11</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">12</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">13</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">14</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">15</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">16</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="2">Baseline, eligibility and safety measures</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>Consent, demographics, medical history, physical exam, psych (MINI)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>Smoking status (FTND, urine cotinine)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>Vital signs, prior and concomitant meds</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>AE/SAE</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Medications and adherence</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>Randomisation</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>Exenatide/placebo administration</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>Nicotine patch dispensation</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>Nicotine patch adherence</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="18">Smoking-related measures and analyses</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>Breath CO</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>Smoking frequency and quantity (TLFB)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>Withdrawal and craving (WSWS, QSU, mCEQ)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>4âweek continuous abstinence</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>7âday point prevalence abstinence</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="2">Weight-related and diet-related measures</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>Weight</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>BMI</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>Waist circumference</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>Weight concerns and efficacy (WCS, WEAQS)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>Food craving (FCI)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>Diet and physical activity (ASA24, GPAQ)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="5">Other measures (self-report and mechanism)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>Psychiatric (PANAS, PHQ-8)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>Mechanism (EEG)</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>Laboratory assessments</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>Urine drug screen, urine cotinine, CBC, CMP, amylase, lipase</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>HbA1C</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>Lipid panel</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>Fingerstick blood glucose</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"><named-content content-type="indent">â</named-content>Urine pregnancy test</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">â</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="T1_FN1">
                      <p>AE, adverse event; ASA24, Automated Self-Administered 24 hours Dietary Assessment Tool; BMI, body mass index; CBC, complete blood count; CMP, complete metabolic panel; CO, carbon monoxide; EEG, electroencephalogram; FCI, Food Craving Inventory; FTND, Fagerstrom Test for Nicotine Dependence; F/U, follow-up; GPAQ, global physical activity questionnaire; HbA1C, glycosylated haemoglobin; mCEQ, Modified Cigarette Evaluation Questionnaire; MINI, Mini-International Neuropsychiatric Interview; NRT, nicotine replacement therapy; PANAS, Positive and Negative Affect Schedule; PHQ, Patient Health Questionnaire; QSU, Questionnaire of Smoking Urges; SAE, serious AE; TLFB, time line follow back; WCS, Weight Concern Scale; WEAQS, Weight Efficacy after Quitting Scale; WSWS, Wisconsin Smoking Withdrawal Questionnaire.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="s2-6">
                <title>Randomisation</title>
                <p>The allocation orders, represented by a randomly assigned blinding coded letter for each treatment condition, will be generated with a pseudorandom number generator and uploaded to an electronic database (REDCap), which will be used to implement randomisation at both sites. The allocation ratio will be 1:1 (exenatide, placebo) and imbalanced randomised orders will be rejected to maintain balanced recruitment.</p>
                <p>Participants, investigators and care givers performing assessments and persons performing data analysis will remain blinded to the participantsâ assigned conditions (exenatide, placebo). An unblinded study nurse will maintain a hard copy of the blinding codes for each treatment condition in a secure, locked location. A password-protected field will also be uploaded to REDCap that maintains the unblinding codes if emergency unblinding is required.</p>
              </sec>
              <sec id="s2-7">
                <title>Intervention</title>
                <sec id="s2-7-1">
                  <title>Exenatide/placebo</title>
                  <p>Exenatide will be purchased commercially as Bydureon for subcutaneous injection and administered at a dose of 2âmg once a week for a total of 14 weeks (2 weeks before the target quit day and 12 weeks post-target quit day). Exenatide is supplied as a powder with a solvent for once-weekly injection. Each single-dose, dual-chamber pen contains 0.65âmg of diluent and 2âmg of exenatide, which remain isolated until mixed. An unblinded study nurse not involved in behavioural counselling, data collection or outcome measurement will prepare and administer medication. Patients will be blindfolded while receiving the injections.</p>
                  <p>Sterile saline (0.9%) will serve as the placebo for exenatide. The placebo will be administered in the same manner and volume as exenatide using insulin syringes.</p>
                </sec>
                <sec id="s2-7-2">
                  <title>Nicotine replacement therapy</title>
                  <p>Nicotine patches (generic) will be purchased commercially and dispensed during clinic visits for 1âweek of use.<xref rid="R27" ref-type="bibr">27</xref> Participants will be instructed to use one patch daily starting 2 weeks before their target quit day for a total of 14 weeks. Participants who smoke &gt;10 cigarettes/day will use 21âmg patches for the first 12 weeks, 14âmg patches for week 13 and 7âmg patches for week 14. Participants who smoke 5â10 cigarettes per day will use 14âmg patches for the first 12 weeks and 7âmg patches for weeks 13 and 14.<xref rid="R28" ref-type="bibr">28</xref> To estimate patch adherence, participants will be instructed to return all used and unused patches.<xref rid="R29" ref-type="bibr">29</xref> Patch adherence will be defined as wearing the patch for â¥6 of 7âdays/week across the 14 weeks.<xref rid="R30" ref-type="bibr">30 31</xref></p>
                </sec>
                <sec id="s2-7-3">
                  <title>Discontinuation of the study medication</title>
                  <p>Discontinuation of the study medication can be decided by either the PI or the participant. Participants who discontinue the study medication will be encouraged to continue with the scheduled visits and assessments to ensure continued counselling and data collection.</p>
                </sec>
                <sec id="s2-7-4">
                  <title>Smoking cession counselling</title>
                  <p>All participants will receive brief individual behavioural smoking cessation counselling based on the US Clinical Practice Guidelines, as recommended for use with pharmacotherapy.<xref rid="R32" ref-type="bibr">32</xref> Counselling will not include recommendations on weight management strategies to directly assess the pharmacological effect of exenatide on changes in weight. The manual-driven counselling protocol has been used in previous studies,<xref rid="R33" ref-type="bibr">33â35</xref> and consists of once a week in-person sessions and 2 brief (10â15âmin) supportive phone calls (at prequit and again at 3âdays postquit), spanning the 14-week active treatment phase. Counselling will be provided by masterâs level clinicians who will be trained by a clinical psychologist (JS) with extensive experience in developing counselling protocols and evaluating behavioural treatment fidelity in clinical trials of substance use disorders.<xref rid="R36" ref-type="bibr">36 37</xref> Counselling sessions will be audiotaped, with 20% of sessions randomly selected to assess adherence and competence.<xref rid="R38" ref-type="bibr">38</xref></p>
                </sec>
                <sec id="s2-7-5">
                  <title>Participant adherence to study procedures</title>
                  <p>Throughout the study, the study staff will remind the participants to follow the study procedures and requirements to ensure participant compliance. If a participant is found to be non-compliant, the she/he will be reminded regarding the importance of following the instructions given.</p>
                </sec>
                <sec id="s2-7-6">
                  <title>Data collection and measures</title>
                  <p>Please refer to <xref rid="T1" ref-type="table">table 1</xref> for time points.</p>
                </sec>
                <sec id="s2-7-7">
                  <title>Smoking-related assessments</title>
                  <p>Baseline smoking status will be assessed via self-reported smoking of â¥5 cigarettes/day for â¥1âyear and confirmed by a urinary cotinine test.</p>
                  <p>Nicotine dependence will be assessed using the Fagerstrom Test for Nicotine Dependence.<xref rid="R39" ref-type="bibr">39</xref></p>
                  <p>Smoking frequency and quantity will be assessed using the time-line follow-back (TLFB) interview methodology.<xref rid="R40" ref-type="bibr">40</xref></p>
                  <p>Breath CO will be assessed using a CO monitor (Micro<sup>+</sup> Smokerlyzer, Williamsburg, Virginia USA).</p>
                  <p>Withdrawal symptoms will be assessed using the Wisconsin Scale of Withdrawal Symptoms (WSWS).<xref rid="R41" ref-type="bibr">41</xref></p>
                  <p>Craving for cigarettes will be evaluated using the Questionnaire of Smoking Urges (QSU).<xref rid="R42" ref-type="bibr">42</xref></p>
                  <p>Smoking satisfaction and psychological reward from smoking in subjects who report smoking between the visits will be evaluated using the Modified Cigarette Evaluation Questionnaire (mCEQ).<xref rid="R43" ref-type="bibr">43</xref></p>
                </sec>
                <sec id="s2-7-8">
                  <title>Weight-related and diet-related assessments</title>
                  <p>Weight (kg) will be measured without shoes using a medical grade digital scale. Height (cm) will be measured without shoes using stadiometer. Waist circumference (cm) will be measured without clothes, midway between the lower rib margin and iliac crest<xref rid="R44" ref-type="bibr">44</xref> using measure tape.</p>
                  <p>Baseline weight concerns and weight efficacy (ie, self-efficacy for preventing PCWG) will be assessed during the screening visit using the Weight Concern Scale (WCS)<xref rid="R7" ref-type="bibr">7</xref> and Weight Efficacy after Quitting Scale,<xref rid="R7" ref-type="bibr">7</xref> respectively.</p>
                  <p>Diet will be assessed using the Automated Self-Administered 24âhours Dietary Assessment Tool.<xref rid="R45" ref-type="bibr">45</xref></p>
                  <p>Craving for food will be assessed using the Food Craving Inventory (FCI).<xref rid="R46" ref-type="bibr">46</xref></p>
                  <p>Physical Activity will be assessed using the WHO Global Physical Activity Questionnaire.<xref rid="R47" ref-type="bibr">47</xref></p>
                </sec>
                <sec id="s2-7-9">
                  <title>Psychiatric/substance use assessments</title>
                  <p>Psychiatric/substance use history will be assessed using the Mini-International Neuropsychiatric Interview.<xref rid="R48" ref-type="bibr">48</xref></p>
                  <p>Depressive Symptoms will be assessed using Patient Health Questionnaire-8 (PHQ-8).<xref rid="R49" ref-type="bibr">49</xref></p>
                  <p>Positive and negative affect will be assessed using the positive and negative affect schedule (PANAS).<xref rid="R50" ref-type="bibr">50</xref></p>
                </sec>
              </sec>
              <sec id="s2-8">
                <title>Laboratory assessments</title>
                <p>Blood tests will include analyses of CBC, CMP, pancreatic enzymes (amylase and lipase), HbA1C, lipids and fingerstick blood glucose; urine tests will include analysis of cotinine, drug screen and pregnancy test in women of childbearing potential; and breath tests will include assessments of CO levels.</p>
                <sec id="s2-8-1">
                  <title>Electroencephalogram</title>
                  <p>EEG will be recorded with a 64-channel actiCAP active electrode cap, amplified with BrainAmp MR and digitised with Brain Vision Recorder (CNRA) or amplified with actiCHamp and digitised with PyCorder (MEDVAMC) (Brain Products, Munich). Procedures for data collection and data reduction will be similar to those used in previous studies.<xref rid="R51" ref-type="bibr">51â56</xref> For each participant, the average ERP will be computed at each scalp site for each category (ie, pleasant, unpleasant, neutral, food and cigarette related) and, in line with previously published reports<xref rid="R57" ref-type="bibr">57 58</xref> and methodological recommendations,<xref rid="R59" ref-type="bibr">59</xref> the amplitude of the late positive potential (LPP) between 400 and 800 ms over a priori selected central and parietal sites will be computed. The steps outlined above for the EEG/ERP data reduction and the statistical analyses on the EEG will be performed using software (ie, BESA, Brain Vision Analyzer, SPSS, STATA, SAS and R) tested in previous studies.</p>
                </sec>
              </sec>
              <sec id="s2-9">
                <title>Outcome measures</title>
                <sec id="s2-9-1">
                  <title>Primary outcomes</title>
                  <list list-type="order">
                    <list-item>
                      <p>Percentage of participants with 4-week continuous abstinence at 12 weeks post-target quit day, defined as no smoking, not even a puff, as measured by self-report (TLFB) and biochemically verified (COâ¤5âppm).</p>
                    </list-item>
                    <list-item>
                      <p>Weight change in kilograms at 12 weeks post-target quit day.</p>
                    </list-item>
                  </list>
                </sec>
                <sec id="s2-9-2">
                  <title>Secondary outcomes</title>
                  <list list-type="order">
                    <list-item>
                      <p>Percentage of participants with 4-week continuous abstinence at 24 weeks post-target quit day as measured by self-report (TLFB) and biochemically verified (COâ¤5âppm).</p>
                    </list-item>
                    <list-item>
                      <p>Weight change in kilograms at 24 weeks post-target quit day.</p>
                    </list-item>
                    <list-item>
                      <p>Amplitude of the late positive potential evoked by visual stimuli.</p>
                    </list-item>
                  </list>
                </sec>
                <sec id="s2-9-3">
                  <title>Other outcomes</title>
                  <list list-type="order">
                    <list-item>
                      <p>Seven-day point prevalence abstinence at 12 and at 24 weeks post-target quit day.</p>
                    </list-item>
                    <list-item>
                      <p>Changes in BMI, waist circumference, HbA1C and serum triglyceride levels.</p>
                    </list-item>
                    <list-item>
                      <p>Smoking satisfaction (mCEQ score) in participants who report smoking between visits.</p>
                    </list-item>
                    <list-item>
                      <p>Craving for cigarettes (QSU score).</p>
                    </list-item>
                    <list-item>
                      <p>Withdrawal symptoms (WSWS score).</p>
                    </list-item>
                    <list-item>
                      <p>Craving for highly palatable food (FCI score).</p>
                    </list-item>
                    <list-item>
                      <p>Depressive symptoms (PHQ-8 score) and affect (PANAS score).</p>
                    </list-item>
                  </list>
                </sec>
              </sec>
              <sec id="s2-10">
                <title>Safety and monitoring</title>
                <sec id="s2-10-1">
                  <title>Medical monitoring</title>
                  <p>Vital signs and overall well-being will be assessed at each visit. Blood glucose levels will be assessed prior to each dose of exenatide. Subsequent doses of the study medication will not be administered if any of the following occur or suspected: acute pancreatitis, hypoglycaemia (blood glucose &lt;70âmg/dL), severe injection site reaction, hypersensitivity reaction, anaphylaxis, angioedema, acute kidney injury or if the study physician believes that there may be any reason to withhold the study medication.</p>
                </sec>
                <sec id="s2-10-2">
                  <title>AE assessment and management</title>
                  <p>Careful clinic procedures will be followed to avoid any potential harm to participants from possible adverse medical or psychological reactions. At each visit, participants will be asked by the study staff if they are experiencing any discomfort or symptoms that might indicate potential side effects of exenatide or NRT. Participants will be withdrawn from study participation if they show signs of serious adverse reactions that pose a threat to their physical or psychological health. Any symptoms or complaints, solicited or spontaneously reported, will be recorded and reported to the IRB and NIDA if events are classified as serious.</p>
                </sec>
                <sec id="s2-10-3">
                  <title>Data collection, entry and storage</title>
                  <p>Checklists will guide study personnel in all procedures for data collection and data management. Whenever possible, questionnaire data are entered directly into the computer by the participant, reducing data entry error. All neurobehavioral data are collected automatically by the computer using professional programmes designed for this purpose and does not allow missing or impossible values. All hand-entered data (miscellaneous study forms) are initially reviewed by the study coordinator for general accuracy and completeness. They are then double entered in REDCap, with any inconsistencies examined and resolved. Data quality will be monitored continuously by the quality control manager and any problems detected will be discussed with the PIs. If necessary, retraining of data collectors will be conducted. Only investigators will have access to the data.</p>
                </sec>
                <sec id="s2-10-4">
                  <title>Data security and plan for protecting confidentiality</title>
                  <p>All data collected on paper forms will be stored in locked cabinets, while electronic data will be stored in REDCap database on a secure password-protected server maintained by the UTHealth Medical School Information Technology Department. Individual participants and their research data will be identified by a unique study identification number (study ID). The study data entry and study management systems will be secured and password protected. The participantsâ contact information will be securely stored for internal use during the study. At the end of the study, all records will continue to be kept in a secure location for as long a period as dictated by IRB and institutional regulations.</p>
                </sec>
              </sec>
              <sec id="s2-11">
                <title>Data monitoring</title>
                <p>The study PI and research team will monitor data on ongoing basis. In addition, a data safety and monitoring board (DSMB) will oversee the ongoing progress of the study. The board consists of two physicians, a psychologist and a biostatistician who are not affiliated with the study or the sponsor. Each member will provide written documentation attesting to absence of conflict of interest. The initial responsibility of the DSMB is to review and approve the initiation of the trial. Thereafter, DSMB evaluations will be conducted on the annual basis. On the study completion, the DSMB will perform end-of-study evaluation. An emergency meeting of the DSMB (open, closed or executive session) may be called at any time by the Chairperson should questions of patient safety arise.</p>
              </sec>
              <sec id="s2-12">
                <title>Trial stopping rules</title>
                <p>The trial may be suspended or prematurely terminated if there is sufficient reasonable cause. Circumstances that may warrant termination or suspension include, but are not limited to determination of unexpected, significant or unacceptable risk to participants; insufficient compliance to protocol requirements; and/or data that are not sufficiently complete and/or evaluable. If the study is suspended, it may resume once concerns about safety, protocol compliance and data quality are addressed and satisfy the suspending party and the IRB.</p>
                <sec id="s2-12-1">
                  <title>Protocol modifications</title>
                  <p>The study PI will receive IRB approval before initiating any changes, including those required by the sponsor, which would affect study participants, such as changes in methods or procedures, numbers of kinds of the study participants, or revisions to the informed consent document or procedures. All protocol revisions will be submitted to the primary sponsor of research.</p>
                </sec>
              </sec>
              <sec id="s2-13">
                <title>Project timeline</title>
                <p>The recruitment for the study began on 7 December 2022; and the estimated primary completion date (final data collection for primary outcome measures) is 31 March 2026. It is anticipated that each site will recruit a minimum of 3 participants (6 participants between the two sites) per month for a total of 216 participants during the 36-month enrolment period. Once randomised, participant duration is 26 weeks.</p>
              </sec>
              <sec id="s2-14">
                <title>Power calculation and sample size</title>
                <sec id="s2-14-1">
                  <title>Assumptions</title>
                  <p>Power considerations for the current trial were calculated to assess the effect of treatment on the primary outcomes in hypothesis 1 (4-week continuous abstinence) and hypothesis 2 (PCWG). Calculations were based on generating k=1000 normal approximations to the Bayesian posterior distribution via Monte Carlo simulation in the R Statistical Computing Environment.<xref rid="R60" ref-type="bibr">60</xref> Statistical power was conceptualised as the percentage of the posterior distributions that met or exceeded a specific probability threshold (described below). All calculations assumed n=172âto account for 20% attrition. Regarding the placebo group effect size for NRT monotherapy (patch &lt;22âmg) in hypothesis 1, the probability of abstinence was set to 0.305.<xref rid="R61" ref-type="bibr">61</xref></p>
                </sec>
                <sec id="s2-14-2">
                  <title>Simulation results</title>
                  <p>Analyses will focus on posterior probabilities â¥0.70 that the effect of exenatide (relative to control) exists for both abstinence and weight. For hypothesis 1, given the assumptions above, calculations determined that the posterior probability met or exceeded 0.70 in 80.3% of simulations where an absolute difference in the probability of abstinence for control (0.305) was 10% lower than that for exenatide (0.405). For hypothesis 2, the same sample size met or exceeded the probability threshold in 84.3% of simulations when assuming a group difference in weight at the end of treatment as small as Cohenâs d=0.20. This study is thus powered to detect a posterior probability PPâ¥70% that exenatide confers at least 10% improvement in abstinence as well as a minimum effect size Cohenâs d=0.20 for lower weight at the end of treatment.</p>
                </sec>
              </sec>
              <sec id="s2-15">
                <title>Statistical analysis plan</title>
                <sec id="s2-15-1">
                  <title>Descriptive statistics and confounding variables</title>
                  <p>Descriptive statistics will evaluate measures of central tendency and frequencies for all continuous and categorical variables (respectively) measured in the study. Preliminary data analyses will inspect relationships between sample characteristics, treatment condition and outcome variables via traditional statistical tests (eg, Ï<sup>2</sup>; Mann-Whitney; t-tests). Any sample characteristics that demonstrate a relationship with both treatment and the outcome variable in a given model meet criteria for being a potential confounder. Sample characteristics that will specifically be evaluated as potential confounders include sex, age, socioeconomic status, smoking heaviness and nicotine dependence, patch adherence, diet, physical activity, baseline BMI, and baseline weight concerns and weight efficacy.<xref rid="R7" ref-type="bibr">7 62â65</xref> Any characteristic that meets the criteria as a potential confounder will result in two models: one with covariate adjustment for that characteristic and a simple model without adjustment. If adjustment does not affect inferences regarding the primary predictor-outcome relationship, the simple model will be retained. If the inferences change, we will report both models. All models will statistically control for the effect of site.</p>
                </sec>
                <sec id="s2-15-2">
                  <title>Inferential paradigm</title>
                  <p>Analyses will use Bayesian statistical inference<xref rid="R66" ref-type="bibr">66 67</xref> to directly yield the probability of an alternative hypothesis given specified prior information. Weakly informative priors will be used as a default (eg, b: ~N[Âµ=0,Ï<sup>2</sup>=100]; for non-linear outcome variables this prior applies to the coefficient within the link-function). Sensitivity analyses using optimistic and pessimistic, sceptical priors will evaluate prior assumptions. Informative priors will use extant information (eg, meta-analytical findings<xref rid="R61" ref-type="bibr">61</xref> for smoking outcomes). Analyses will use effective sample size and scale reduction factors to assess convergence.</p>
                </sec>
                <sec id="s2-15-3">
                  <title>Statistical modelling</title>
                  <p>Analyses will primarily use generalised linear modelling (GLM) with multilevel components (GLMM) for correlated observations. Multilevel models will incorporate random effects (eg, a level 2 intercept for correlated observations) as needed. Potentially non-linear relationships between predictors and outcomes will be evaluated via inclusion of polynomial or spline effects. Evaluation of distributional assumptions will use residual plots, formal statistical tests and posterior predictive checking. Violations of assumptions will be addressed via transformation, robust estimation, stratification and/or coefficient scaling where appropriate. GLM/GLMM will be performed using the R statistical computing environment via rstan<xref rid="R68" ref-type="bibr">68</xref> and brms.<xref rid="R69" ref-type="bibr">69</xref></p>
                </sec>
              </sec>
              <sec id="s2-16">
                <title>Missingness, multiplicity and secondary analyses</title>
                <sec id="s2-16-1">
                  <title>Intentionion-to-treat analyses</title>
                  <p>Will be conducted to provide estimates of treatment effects that are unbiased with respect to non-random drop out. Individuals that drop out of the trial will be imputed as continuing to smoke. A per-protocol secondary analysis will provide an optimistic estimate of treatment effects. Missing data will be addressed via explicit modelling of missingness or imputation where appropriate. Each approach is robust to ignorable missingness (ie, missing completely at random (MCAR) and missing at random (MAR)). Sensitivity analyses will permit evaluation of the robustness of findings to missing data assumptions. Due to its observation of the likelihood principle,<xref rid="R70" ref-type="bibr">70</xref> Bayesian analyses are less influenced by multiplicity; instead, all specified analyses are evaluated via a probability threshold of interest defined above. Secondary analyses will evaluate differences between abstainers and non-abstainers regarding all outcome variables, as well as potential interactions between treatment and baseline sample characteristics. Such analyses will retain the same probability threshold defined for the primary analyses, with exploratory credence given to higher thresholds.</p>
                </sec>
              </sec>
              <sec id="s2-17">
                <title>Specific analyses</title>
                <sec id="s2-17-1">
                  <title>Specific aim 1: hypothesis 1</title>
                  <p>Compared with placebo, treatment with exenatide will result in a higher rate of 4-week continuous abstinence (self-reported and biochemically verified) at 12 weeks post-target quit day. GLM will evaluate 4-week continuous abstinence (yes vs no) as a function of treatment condition. Follow-up analyses will evaluate the trajectory of abstinence over time via GLMM.</p>
                </sec>
                <sec id="s2-17-2">
                  <title>Specific aim 2: hypothesis 2</title>
                  <p>Compared with placebo, treatment with exenatide will be associated with reduced PCWG at 12 weeks post-target quit day. GLM will evaluate residual change by modelling end of treatment weight as a function of treatment condition, controlling for baseline. GLMM will evaluate follow-up analyses of longitudinal changes in weight between groups over time.</p>
                </sec>
                <sec id="s2-17-3">
                  <title>Exploratory aim 3: hypothesis 3a</title>
                  <p>Compared with placebo, treatment with exenatide will result in a higher rate of 4-week continuous abstinence at 24 weeks post-target quit day. Analyses follow from those stated above for hypothesis 1, with the outcomes evaluated at 24 weeks post-target quit day instead of 12 weeks. GLM will evaluate 4-week continuous abstinence (yes vs no) as a function of treatment condition, and GLMM will evaluate the trajectory of abstinence over time.</p>
                </sec>
                <sec id="s2-17-4">
                  <title>Exploratory aim 3: hypothesis 3b</title>
                  <p>Compared with placebo, treatment with exenatide will be associated with a lower PCW at 24 weeks post-target quit day. Analyses follow from those stated above for hypothesis 2, with the outcomes evaluated at 24 weeks post-target quit day instead of 12 weeks. GLM will evaluate residual change by modelling treatment weight as a function of treatment condition, controlling for baseline, and GLMM will evaluate longitudinal changes in weight between groups over time.</p>
                </sec>
                <sec id="s2-17-5">
                  <title>Exploratory aim 4: hypothesis 4</title>
                  <p>Treatment with exenatide will be associated with an attenuation of ERP reactivity specific to nicotine-related and food-related stimuli at week 3 relative to baseline. Multivariate GLM will evaluate patterns of responses across different types of stimuli as a function of treatment group.</p>
                </sec>
              </sec>
              <sec id="s2-18">
                <title>Interim analyses</title>
                <p>Not applicable for this trial.</p>
              </sec>
              <sec id="s2-19">
                <title>Patient and public involvement</title>
                <p>None.</p>
              </sec>
              <sec id="s2-20">
                <title>Ethics and dissemination</title>
                <p>The study approval has been received from the UTHealth Committee for the Protection of Human Subjects (HSC-MS-21-0639) and Baylor College of Medicine Institutional Review Board (H-50543). All participants will sign informed consent. The study is registered on ClinicalTrials.gov, NCT05610800. The study results will be disseminated via peer-reviewed publications and conference presentations.</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="s3">
              <title>Discussion</title>
              <p>Preclinical data showing that GLP-1RAs attenuate the reinforcing effects of food and nicotine, coupled with the results of the first human study that demonstrated the positive effects of exenatide treatment on smoking and weight outcomes, provide a strong premise for targeting GLP-1 receptors to facilitate smoking abstinence and mitigate PCW. Building on our previous 6-week trial of exenatide,<xref rid="R25" ref-type="bibr">25</xref> the current study will include a longer, 14-week, treatment duration and a post-treatment follow-up at 12 weeks after the end of treatment. In addition to examining the impact of exenatide on smoking abstinence and PCWG, this trial will explore putative mechanisms by which exenatide might modulate smoking and weight outcomes. The most compelling preclinical evidence to date suggests attenuation of responding in brain networks related to reward processing as a plausible mechanism of action. By measuring ERP reactivity to nicotine-related and food-related stimuli, we aim to interrogate reward-relevant cortical regions by which exenatide might reduce smoking and mitigate PCWG.</p>
              <p>We note three key limitations of this study. First, the trialâs focus on individuals with pre-diabetes and/or overweight may limit the generalisability of the findings. Second, administration of the study medication during in-clinic visits will not allow assessment of acceptability and adherence to a subcutaneously administered therapy for smoking cessation and weight management in the real world. Third, the 14-week treatment duration and the 12-week post-end-of-treatment follow-up periods are relatively short. If the hypotheses of this study are confirmed, subsequent research would require examination of exenatide over a longer treatment period and a post-treatment follow-up to ascertain the optimal length of therapy and the sustainability of exenatideâs effects.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material content-type="local-data" id="d64e209">
                <caption>
                  <title>Reviewer comments</title>
                </caption>
                <media xlink:href="bmjopen-2023-072707.reviewer_comments.pdf"/>
              </supplementary-material>
              <supplementary-material content-type="local-data" id="d64e210">
                <caption>
                  <title>Author's
manuscript</title>
                </caption>
                <media xlink:href="bmjopen-2023-072707.draft_revisions.pdf"/>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <fn-group>
              <fn fn-type="other">
                <p><bold>Contributors:</bold> According to the definition given by the International Committee of Medical Journal Editors, all the authors qualify for authorship. LY designed the study and wrote the first draft of the study protocol. CDV, FV and JS made substantial contributions to the overall study design. FV and HEW designed the EEG paradigm. PMC developed the smoking cessation counselling protocol. RS undertook the statistical power calculation and statistical analysis plan. LY wrote the first draft of the manuscript based on the study protocol. CDV, FV, RS, MFW, TK, HA, SDL and JS contributed with manuscript revisions and important intellectual content. All authors have approved the final manuscript.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Funding:</bold> National Institutes of Health, National Institute of Drug Abuse, 1R01DA053241-01A1.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Disclaimer:</bold> The sponsor has no role in the study design; collection, analysis, and interpretation of data; writing of this report; or the decision to submit the report for publication.</p>
              </fn>
              <fn fn-type="COI-statement">
                <p><bold>Competing interests:</bold> None declared.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Patient and public involvement:</bold> Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Provenance and peer review:</bold> Not commissioned; peer reviewed for ethical and funding approval prior to submission.</p>
              </fn>
              <fn fn-type="other">
                <p><bold>Supplemental material:</bold> This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.</p>
              </fn>
            </fn-group>
            <sec sec-type="ethics-statement">
              <title>Ethics statements</title>
              <sec>
                <title>Patient consent for publication</title>
                <p content-type="ethics-consent-to-publish">Not applicable.</p>
              </sec>
            </sec>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fryar</surname><given-names>C</given-names></string-name>, <string-name><surname>Afful</surname><given-names>J</given-names></string-name></person-group>. <article-title>Prevalence of overweight, obesity, and severe obesity among adults aged 20 and over: United States, 1960â1962 through 2017â2018</article-title>. <source>NCHS Health E-Stats</source><year>2020</year>.</mixed-citation>
              </ref>
              <ref id="R2">
                <label>2</label>
                <mixed-citation publication-type="webpage"><article-title>Smoking cessation: a report of the surgeon general</article-title>. <year>2020</year>. <comment>Available</comment>: <uri xlink:href="https://www.cdc.gov/tobacco/data_statistics/sgr/2020-smoking-cessation/?s_cid=OSH_misc_m180">https://www.cdc.gov/tobacco/data_statistics/sgr/2020-smoking-cessation/?s_cid=OSH_misc_m180</uri></mixed-citation>
              </ref>
              <ref id="R3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Aubin</surname><given-names>HJ</given-names></string-name>, <string-name><surname>Farley</surname><given-names>A</given-names></string-name>, <string-name><surname>Lycett</surname><given-names>D</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Weight gain in Smokers after quitting cigarettes: meta-analysis</article-title>. <source>BMJ</source><year>2012</year>;<volume>345</volume>:<elocation-id>e4439</elocation-id>. <pub-id pub-id-type="doi">10.1136/bmj.e4439</pub-id><pub-id pub-id-type="pmid">22782848</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Harris</surname><given-names>KK</given-names></string-name>, <string-name><surname>Zopey</surname><given-names>M</given-names></string-name>, <string-name><surname>Friedman</surname><given-names>TC</given-names></string-name></person-group>. <article-title>Metabolic effects of smoking cessation</article-title>. <source>Nat Rev Endocrinol</source><year>2016</year>;<volume>12</volume>:<elocation-id>684</elocation-id>. <pub-id pub-id-type="doi">10.1038/nrendo.2016.171</pub-id><pub-id pub-id-type="pmid">27688045</pub-id></mixed-citation>
              </ref>
              <ref id="R5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Siahpush</surname><given-names>M</given-names></string-name>, <string-name><surname>Singh</surname><given-names>GK</given-names></string-name>, <string-name><surname>Tibbits</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>It is better to be a fat ex-smoker than a thin smoker: findings from the 1997-2004 national health interview survey-national death index linkage study</article-title>. <source>Tob Control</source><year>2014</year>;<volume>23</volume>:<fpage>395</fpage>â<lpage>402</lpage>. <pub-id pub-id-type="doi">10.1136/tobaccocontrol-2012-050912</pub-id><pub-id pub-id-type="pmid">23574644</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pomerleau</surname><given-names>CS</given-names></string-name>, <string-name><surname>Zucker</surname><given-names>AN</given-names></string-name>, <string-name><surname>Stewart</surname><given-names>AJ</given-names></string-name></person-group>. <article-title>Characterizing concerns about post-cessation weight gain: results from a national survey of women Smokers</article-title>. <source>Nicotine Tob Res</source><year>2001</year>;<volume>3</volume>:<fpage>51</fpage>â<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1080/14622200020032105</pub-id><pub-id pub-id-type="pmid">11260811</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Borrelli</surname><given-names>B</given-names></string-name>, <string-name><surname>Mermelstein</surname><given-names>R</given-names></string-name></person-group>. <article-title>The role of weight concern and self-efficacy in smoking cessation and weight gain among Smokers in a clinic-based cessation program</article-title>. <source>Addict Behav</source><year>1998</year>;<volume>23</volume>:<fpage>609</fpage>â<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/s0306-4603(98)00014-8</pub-id><pub-id pub-id-type="pmid">9768298</pub-id></mixed-citation>
              </ref>
              <ref id="R8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>NÃ¸rregaard</surname><given-names>J</given-names></string-name>, <string-name><surname>TÃ¸nnesen</surname><given-names>P</given-names></string-name>, <string-name><surname>Petersen</surname><given-names>L</given-names></string-name></person-group>. <article-title>Predictors and reasons for relapse in smoking cessation with nicotine and placebo patches</article-title>. <source>Prev Med</source><year>1993</year>;<volume>22</volume>:<fpage>261</fpage>â<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1006/pmed.1993.1021</pub-id><pub-id pub-id-type="pmid">8483863</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Calarco</surname><given-names>CA</given-names></string-name>, <string-name><surname>Picciotto</surname><given-names>MR</given-names></string-name></person-group>. <article-title>Nicotinic acetylcholine receptor signaling in the hypothalamus: mechanisms related to nicotineâs effects on food intake</article-title>. <source>Nicotine Tob Res</source><year>2020</year>;<volume>22</volume>:<fpage>152</fpage>â<lpage>63</lpage>. <pub-id pub-id-type="doi">10.1093/ntr/ntz010</pub-id><pub-id pub-id-type="pmid">30690485</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hu</surname><given-names>Y</given-names></string-name>, <string-name><surname>Zong</surname><given-names>G</given-names></string-name>, <string-name><surname>Liu</surname><given-names>G</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Smoking cessation, weight change, type 2 diabetes, and mortality</article-title>. <source>N Engl J Med</source><year>2018</year>;<volume>379</volume>:<fpage>623</fpage>â<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1803626</pub-id><pub-id pub-id-type="pmid">30110591</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bush</surname><given-names>T</given-names></string-name>, <string-name><surname>Lovejoy</surname><given-names>JC</given-names></string-name>, <string-name><surname>Deprey</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The effect of tobacco cessation on weight gain, obesity, and diabetes risk</article-title>. <source>Obesity</source><year>2016</year>;<volume>24</volume>:<fpage>1834</fpage>â<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1002/oby.21582</pub-id><pub-id pub-id-type="pmid">27569117</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yeh</surname><given-names>HC</given-names></string-name>, <string-name><surname>Duncan</surname><given-names>BB</given-names></string-name>, <string-name><surname>Schmidt</surname><given-names>MI</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Smoking, smoking cessation, and risk for type 2 diabetes mellitus: a cohort study</article-title>. <source>Ann Intern Med</source><year>2010</year>;<volume>152</volume>:<fpage>10</fpage>â<lpage>7</lpage>. <pub-id pub-id-type="doi">10.7326/0003-4819-152-1-201001050-00005</pub-id><pub-id pub-id-type="pmid">20048267</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hur</surname><given-names>NW</given-names></string-name>, <string-name><surname>Kim</surname><given-names>HC</given-names></string-name>, <string-name><surname>Nam</surname><given-names>CM</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Smoking cessation and risk of type 2 diabetes mellitus: Korea medical insurance corporation study</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source><year>2007</year>;<volume>14</volume>:<fpage>244</fpage>â<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1097/01.hjr.0000239474.41379.79</pub-id><pub-id pub-id-type="pmid">17446803</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pan</surname><given-names>A</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Talaei</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Relation of active, passive, and quitting smoking with incident type 2 diabetes: a systematic review and meta-analysis</article-title>. <source>Lancet Diabetes Endocrinol</source><year>2015</year>;<volume>3</volume>:<fpage>958</fpage>â<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1016/S2213-8587(15)00316-2</pub-id><pub-id pub-id-type="pmid">26388413</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Reimann</surname><given-names>F</given-names></string-name></person-group>. <article-title>Molecular mechanisms underlying nutrient detection by Incretin-Secreting cells</article-title>. <source>Int Dairy J</source><year>2010</year>;<volume>20</volume>:<fpage>236</fpage>â<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.idairyj.2009.11.014</pub-id><pub-id pub-id-type="pmid">20204054</pub-id></mixed-citation>
              </ref>
              <ref id="R16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Han</surname><given-names>VK</given-names></string-name>, <string-name><surname>Hynes</surname><given-names>MA</given-names></string-name>, <string-name><surname>Jin</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Cellular localization of Proglucagon/glucagon-like peptide I messenger Rnas in rat brain</article-title>. <source>J Neurosci Res</source><year>1986</year>;<volume>16</volume>:<fpage>97</fpage>â<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1002/jnr.490160110</pub-id><pub-id pub-id-type="pmid">2427741</pub-id></mixed-citation>
              </ref>
              <ref id="R17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Larsen</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Tang-Christensen</surname><given-names>M</given-names></string-name>, <string-name><surname>Holst</surname><given-names>JJ</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Distribution of glucagon-like Peptide-1 and other Preproglucagon-derived peptides in the rat hypothalamus and brainstem</article-title>. <source>Neuroscience</source><year>1997</year>;<volume>77</volume>:<fpage>257</fpage>â<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1016/S0306-4522(96)00434-4</pub-id><pub-id pub-id-type="pmid">9044391</pub-id></mixed-citation>
              </ref>
              <ref id="R18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jin</surname><given-names>SL</given-names></string-name>, <string-name><surname>Han</surname><given-names>VK</given-names></string-name>, <string-name><surname>Simmons</surname><given-names>JG</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Distribution of Glucagonlike peptide I (GLP-I), glucagon, and Glicentin in the rat brain: an Immunocytochemical study</article-title>. <source>J Comp Neurol</source><year>1988</year>;<volume>271</volume>:<fpage>519</fpage>â<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1002/cne.902710405</pub-id><pub-id pub-id-type="pmid">3385016</pub-id></mixed-citation>
              </ref>
              <ref id="R19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>van Bloemendaal</surname><given-names>L</given-names></string-name>, <string-name><surname>IJzerman</surname><given-names>RG</given-names></string-name>, <string-name><surname>Ten Kulve</surname><given-names>JS</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>GLP-1 receptor activation modulates Appetite- and reward-related brain areas in humans</article-title>. <source>Diabetes</source><year>2014</year>;<volume>63</volume>:<fpage>4186</fpage>â<lpage>96</lpage>. <pub-id pub-id-type="doi">10.2337/db14-0849</pub-id><pub-id pub-id-type="pmid">25071023</pub-id></mixed-citation>
              </ref>
              <ref id="R20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Andersen</surname><given-names>A</given-names></string-name>, <string-name><surname>Lund</surname><given-names>A</given-names></string-name>, <string-name><surname>Knop</surname><given-names>FK</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Glucagon-like peptide 1 in health and disease</article-title>. <source>Nat Rev Endocrinol</source><year>2018</year>;<volume>14</volume>:<fpage>390</fpage>â<lpage>403</lpage>. <pub-id pub-id-type="doi">10.1038/s41574-018-0016-2</pub-id><pub-id pub-id-type="pmid">29728598</pub-id></mixed-citation>
              </ref>
              <ref id="R21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Merchenthaler</surname><given-names>I</given-names></string-name>, <string-name><surname>Lane</surname><given-names>M</given-names></string-name>, <string-name><surname>Shughrue</surname><given-names>P</given-names></string-name></person-group>. <article-title>Distribution of pre-pro-glucagon and glucagon-like Peptide-1 receptor messenger Rnas in the rat central nervous system</article-title>. <source>J Comp Neurol</source><year>1999</year>;<volume>403</volume>:<fpage>261</fpage>â<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1002/(sici)1096-9861(19990111)403:2&lt;261::aid-cne8&gt;3.0.co;2-5</pub-id><pub-id pub-id-type="pmid">9886047</pub-id></mixed-citation>
              </ref>
              <ref id="R22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Alhadeff</surname><given-names>AL</given-names></string-name>, <string-name><surname>Rupprecht</surname><given-names>LE</given-names></string-name>, <string-name><surname>Hayes</surname><given-names>MR</given-names></string-name></person-group>. <article-title>GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral Tegmental area and nucleus accumbens to control for food intake</article-title>. <source>Endocrinology</source><year>2012</year>;<volume>153</volume>:<fpage>647</fpage>â<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1210/en.2011-1443</pub-id><pub-id pub-id-type="pmid">22128031</pub-id></mixed-citation>
              </ref>
              <ref id="R23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tuesta</surname><given-names>LM</given-names></string-name>, <string-name><surname>Chen</surname><given-names>Z</given-names></string-name>, <string-name><surname>Duncan</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>GLP-1 acts on Habenular avoidance circuits to control nicotine intake</article-title>. <source>Nat Neurosci</source><year>2017</year>;<volume>20</volume>:<fpage>708</fpage>â<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1038/nn.4540</pub-id><pub-id pub-id-type="pmid">28368384</pub-id></mixed-citation>
              </ref>
              <ref id="R24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Egecioglu</surname><given-names>E</given-names></string-name>, <string-name><surname>Engel</surname><given-names>JA</given-names></string-name>, <string-name><surname>Jerlhag</surname><given-names>E</given-names></string-name></person-group>. <article-title>The glucagon-like peptide 1 analogue Exendin-4 attenuates the nicotine-induced locomotor stimulation, Accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice</article-title>. <source>PLoS One</source><year>2013</year>;<volume>8</volume>:<elocation-id>e77284</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0077284</pub-id><pub-id pub-id-type="pmid">24204788</pub-id></mixed-citation>
              </ref>
              <ref id="R25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yammine</surname><given-names>L</given-names></string-name>, <string-name><surname>Green</surname><given-names>CE</given-names></string-name>, <string-name><surname>Kosten</surname><given-names>TR</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Exenatide adjunct to nicotine patch facilitates smoking cessation and may reduce post-cessation weight gain</article-title>. <source>Nicotine &amp; Tobacco Research</source><year>2021</year>;<volume>23</volume>:<fpage>1682</fpage>â<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1093/ntr/ntab066</pub-id><pub-id pub-id-type="pmid">33831213</pub-id></mixed-citation>
              </ref>
              <ref id="R26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Insel</surname><given-names>TR</given-names></string-name></person-group>. <article-title>The NIMH experimental medicine initiative</article-title>. <source>World Psychiatry</source><year>2015</year>;<volume>14</volume>:<fpage>151</fpage>â<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1002/wps.20227</pub-id><pub-id pub-id-type="pmid">26043323</pub-id></mixed-citation>
              </ref>
              <ref id="R27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gray</surname><given-names>KM</given-names></string-name>, <string-name><surname>McClure</surname><given-names>EA</given-names></string-name>, <string-name><surname>Baker</surname><given-names>NL</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>An exploratory short-term double-blind randomized trial of Varenicline versus nicotine patch for smoking cessation in women</article-title>. <source>Addiction</source><year>2015</year>;<volume>110</volume>:<fpage>1027</fpage>â<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1111/add.12895</pub-id><pub-id pub-id-type="pmid">25727442</pub-id></mixed-citation>
              </ref>
              <ref id="R28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Baker</surname><given-names>TB</given-names></string-name>, <string-name><surname>Piper</surname><given-names>ME</given-names></string-name>, <string-name><surname>Stein</surname><given-names>JH</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Effects of nicotine patch vs Varenicline vs combination nicotine replacement therapy on smoking cessation at 26 weeks: A randomized clinical trial</article-title>. <source>JAMA</source><year>2016</year>;<volume>315</volume>:<fpage>371</fpage>â<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2015.19284</pub-id><pub-id pub-id-type="pmid">26813210</pub-id></mixed-citation>
              </ref>
              <ref id="R29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hatsukami</surname><given-names>D</given-names></string-name>, <string-name><surname>Mooney</surname><given-names>M</given-names></string-name>, <string-name><surname>Murphy</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Effects of high dose transdermal nicotine replacement in cigarette Smokers</article-title>. <source>Pharmacology Biochemistry and Behavior</source><year>2007</year>;<volume>86</volume>:<fpage>132</fpage>â<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.pbb.2006.12.017</pub-id><pub-id pub-id-type="pmid">17267026</pub-id></mixed-citation>
              </ref>
              <ref id="R30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Handschin</surname><given-names>J</given-names></string-name>, <string-name><surname>Hitsman</surname><given-names>B</given-names></string-name>, <string-name><surname>Blazekovic</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Factors associated with adherence to transdermal nicotine patches within a smoking cessation effectiveness trial</article-title>. <source>J Smok Cessat</source><year>2018</year>;<volume>13</volume>:<fpage>33</fpage>â<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1017/jsc.2017.2</pub-id><pub-id pub-id-type="pmid">31223345</pub-id></mixed-citation>
              </ref>
              <ref id="R31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kaufmann</surname><given-names>A</given-names></string-name>, <string-name><surname>Hitsman</surname><given-names>B</given-names></string-name>, <string-name><surname>Goelz</surname><given-names>PM</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Rate of nicotine metabolism and smoking cessation outcomes in a community-based sample of treatment-seeking Smokers</article-title>. <source>Addict Behav</source><year>2015</year>;<volume>51</volume>:<fpage>93</fpage>â<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.addbeh.2015.07.019</pub-id><pub-id pub-id-type="pmid">26240944</pub-id></mixed-citation>
              </ref>
              <ref id="R32">
                <label>32</label>
                <mixed-citation publication-type="journal"><article-title>Treating tobacco use and dependence: 2008 update U.S. public health service clinical practice guideline executive summary</article-title>. <source>Respir Care</source><year>2008</year>;<volume>53</volume>:<fpage>1217</fpage>â<lpage>22</lpage>.<pub-id pub-id-type="pmid">18807274</pub-id></mixed-citation>
              </ref>
              <ref id="R33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cinciripini</surname><given-names>PM</given-names></string-name>, <string-name><surname>Tsoh</surname><given-names>JY</given-names></string-name>, <string-name><surname>Wetter</surname><given-names>DW</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Combined effects of venlafaxine, nicotine replacement, and brief counseling on smoking cessation</article-title>. <source>Exp Clin Psychopharmacol</source><year>2005</year>;<volume>13</volume>:<fpage>282</fpage>â<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1037/1064-1297.13.4.282</pub-id><pub-id pub-id-type="pmid">16366758</pub-id></mixed-citation>
              </ref>
              <ref id="R34">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cinciripini</surname><given-names>PM</given-names></string-name>, <string-name><surname>Blalock</surname><given-names>JA</given-names></string-name>, <string-name><surname>Minnix</surname><given-names>JA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Effects of an intensive depression-focused intervention for smoking cessation in pregnancy</article-title>. <source>J Consult Clin Psychol</source><year>2010</year>;<volume>78</volume>:<fpage>44</fpage>â<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1037/a0018168</pub-id><pub-id pub-id-type="pmid">20099949</pub-id></mixed-citation>
              </ref>
              <ref id="R35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cinciripini</surname><given-names>PM</given-names></string-name>, <string-name><surname>Robinson</surname><given-names>JD</given-names></string-name>, <string-name><surname>Karam-Hage</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Effects of Varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal</article-title>. <source>JAMA Psychiatry</source><year>2013</year>;<volume>70</volume>:<fpage>522</fpage>â<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1001/jamapsychiatry.2013.678</pub-id><pub-id pub-id-type="pmid">23536105</pub-id></mixed-citation>
              </ref>
              <ref id="R36">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stotts</surname><given-names>AL</given-names></string-name>, <string-name><surname>Schmitz</surname><given-names>JM</given-names></string-name>, <string-name><surname>Rhoades</surname><given-names>HM</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Motivational interviewing with cocaine-dependent patients: a pilot study</article-title>. <source>J Consult Clin Psychol</source><year>2001</year>;<volume>69</volume>:<fpage>858</fpage>â<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1037//0022-006x.69.5.858</pub-id><pub-id pub-id-type="pmid">11680565</pub-id></mixed-citation>
              </ref>
              <ref id="R37">
                <label>37</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stotts</surname><given-names>AL</given-names></string-name>, <string-name><surname>DeLaune</surname><given-names>KA</given-names></string-name>, <string-name><surname>Schmitz</surname><given-names>JM</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Impact of a motivational intervention on mechanisms of change in low-income pregnant Smokers</article-title>. <source>Addict Behav</source><year>2004</year>;<volume>29</volume>:<fpage>1649</fpage>â<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1016/j.addbeh.2004.02.063</pub-id><pub-id pub-id-type="pmid">15451133</pub-id></mixed-citation>
              </ref>
              <ref id="R38">
                <label>38</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Collins</surname><given-names>SE</given-names></string-name>, <string-name><surname>Eck</surname><given-names>S</given-names></string-name>, <string-name><surname>Kick</surname><given-names>E</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Implementation of a smoking cessation treatment integrity protocol: treatment Discriminability, potency and manual adherence</article-title>. <source>Addict Behav</source><year>2009</year>;<volume>34</volume>:<fpage>477</fpage>â<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1016/j.addbeh.2008.12.008</pub-id><pub-id pub-id-type="pmid">19162408</pub-id></mixed-citation>
              </ref>
              <ref id="R39">
                <label>39</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Heatherton</surname><given-names>TF</given-names></string-name>, <string-name><surname>Kozlowski</surname><given-names>LT</given-names></string-name>, <string-name><surname>Frecker</surname><given-names>RC</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire</article-title>. <source>Br J Addict</source><year>1991</year>;<volume>86</volume>:<fpage>1119</fpage>â<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1111/j.1360-0443.1991.tb01879.x</pub-id><pub-id pub-id-type="pmid">1932883</pub-id></mixed-citation>
              </ref>
              <ref id="R40">
                <label>40</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sobell</surname><given-names>LC</given-names></string-name>, <string-name><surname>Sobell</surname><given-names>MB</given-names></string-name>, <string-name><surname>Leo</surname><given-names>GI</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Reliability of a Timeline method: assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations</article-title>. <source>Br J Addict</source><year>1988</year>;<volume>83</volume>:<fpage>393</fpage>â<lpage>402</lpage>. <pub-id pub-id-type="doi">10.1111/j.1360-0443.1988.tb00485.x</pub-id><pub-id pub-id-type="pmid">3395719</pub-id></mixed-citation>
              </ref>
              <ref id="R41">
                <label>41</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Welsch</surname><given-names>SK</given-names></string-name>, <string-name><surname>Smith</surname><given-names>SS</given-names></string-name>, <string-name><surname>Wetter</surname><given-names>DW</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Development and validation of the Wisconsin smoking withdrawal scale</article-title>. <source>Exp Clin Psychopharmacol</source><year>1999</year>;<volume>7</volume>:<fpage>354</fpage>â<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1037//1064-1297.7.4.354</pub-id><pub-id pub-id-type="pmid">10609970</pub-id></mixed-citation>
              </ref>
              <ref id="R42">
                <label>42</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cox</surname><given-names>LS</given-names></string-name>, <string-name><surname>Tiffany</surname><given-names>ST</given-names></string-name>, <string-name><surname>Christen</surname><given-names>AG</given-names></string-name></person-group>. <article-title>Evaluation of the brief questionnaire of smoking URGES (QSU-brief) in laboratory and clinical settings</article-title>. <source>Nicotine Tob Res</source><year>2001</year>;<volume>3</volume>:<fpage>7</fpage>â<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1080/14622200020032051</pub-id><pub-id pub-id-type="pmid">11260806</pub-id></mixed-citation>
              </ref>
              <ref id="R43">
                <label>43</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cappelleri</surname><given-names>JC</given-names></string-name>, <string-name><surname>Bushmakin</surname><given-names>AG</given-names></string-name>, <string-name><surname>Baker</surname><given-names>CL</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Confirmatory factor analyses and reliability of the modified cigarette evaluation questionnaire</article-title>. <source>Addict Behav</source><year>2007</year>;<volume>32</volume>:<fpage>912</fpage>â<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1016/j.addbeh.2006.06.028</pub-id><pub-id pub-id-type="pmid">16875787</pub-id></mixed-citation>
              </ref>
              <ref id="R44">
                <label>44</label>
                <mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Health Organisation</collab></person-group>. <year>2008</year>. <comment>Available</comment>: <uri xlink:href="https://www.who.int/nutrition/publications/obesity/WHO_report_waistcircumference_and_waisthip_ratio/en">https://www.who.int/nutrition/publications/obesity/WHO_report_waistcircumference_and_waisthip_ratio/en</uri></mixed-citation>
              </ref>
              <ref id="R45">
                <label>45</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kirkpatrick</surname><given-names>SI</given-names></string-name>, <string-name><surname>Subar</surname><given-names>AF</given-names></string-name>, <string-name><surname>Douglass</surname><given-names>D</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Performance of the automated self-administered 24-hour recall relative to a measure of true intakes and to an interviewer-administered 24-H recall</article-title>. <source>Am J Clin Nutr</source><year>2014</year>;<volume>100</volume>:<fpage>233</fpage>â<lpage>40</lpage>. <pub-id pub-id-type="doi">10.3945/ajcn.114.083238</pub-id><pub-id pub-id-type="pmid">24787491</pub-id></mixed-citation>
              </ref>
              <ref id="R46">
                <label>46</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>White</surname><given-names>MA</given-names></string-name>, <string-name><surname>Whisenhunt</surname><given-names>BL</given-names></string-name>, <string-name><surname>Williamson</surname><given-names>DA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Development and validation of the food-craving inventory</article-title>. <source>Obes Res</source><year>2002</year>;<volume>10</volume>:<fpage>107</fpage>â<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1038/oby.2002.17</pub-id><pub-id pub-id-type="pmid">11836456</pub-id></mixed-citation>
              </ref>
              <ref id="R47">
                <label>47</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Armstrong</surname><given-names>T</given-names></string-name>, <string-name><surname>Bull</surname><given-names>F</given-names></string-name></person-group>. <article-title>Development of the world health organization global physical activity questionnaire (GPAQ)</article-title>. <source>J Public Health</source><year>2006</year>;<volume>14</volume>:<fpage>66</fpage>â<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1007/s10389-006-0024-x</pub-id></mixed-citation>
              </ref>
              <ref id="R48">
                <label>48</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sheehan</surname><given-names>DV</given-names></string-name>, <string-name><surname>Lecrubier</surname><given-names>Y</given-names></string-name>, <string-name><surname>Sheehan</surname><given-names>KH</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The mini-International neuropsychiatric interview (M.I.N.I): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10</article-title>. <source>J Clin Psychiatry</source><year>1998</year>;<volume>59 Suppl 20</volume>:<fpage>22</fpage>â<lpage>33</lpage>;</mixed-citation>
              </ref>
              <ref id="R49">
                <label>49</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kroenke</surname><given-names>K</given-names></string-name>, <string-name><surname>Strine</surname><given-names>TW</given-names></string-name>, <string-name><surname>Spitzer</surname><given-names>RL</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The PHQ-8 as a measure of current depression in the general population</article-title>. <source>J Affect Disord</source><year>2009</year>;<volume>114</volume>:<fpage>163</fpage>â<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/j.jad.2008.06.026</pub-id><pub-id pub-id-type="pmid">18752852</pub-id></mixed-citation>
              </ref>
              <ref id="R50">
                <label>50</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Watson</surname><given-names>D</given-names></string-name>, <string-name><surname>Clark</surname><given-names>LA</given-names></string-name>, <string-name><surname>Tellegen</surname><given-names>A</given-names></string-name></person-group>. <article-title>Development and validation of brief measures of positive and negative affect: the PANAS scales</article-title>. <source>J Pers Soc Psychol</source><year>1988</year>;<volume>54</volume>:<fpage>1063</fpage>â<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1037//0022-3514.54.6.1063</pub-id><pub-id pub-id-type="pmid">3397865</pub-id></mixed-citation>
              </ref>
              <ref id="R51">
                <label>51</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Webber</surname><given-names>HE</given-names></string-name>, <string-name><surname>de Dios</surname><given-names>C</given-names></string-name>, <string-name><surname>Wardle</surname><given-names>MC</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Electrophysiological responses to emotional and cocaine cues reveal individual Neuroaffective profiles in cocaine users</article-title>. <source>Exp Clin Psychopharmacol</source><year>2022</year>;<volume>30</volume>:<fpage>514</fpage>â<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1037/pha0000450</pub-id><pub-id pub-id-type="pmid">33630644</pub-id></mixed-citation>
              </ref>
              <ref id="R52">
                <label>52</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gibney</surname><given-names>KD</given-names></string-name>, <string-name><surname>Kypriotakis</surname><given-names>G</given-names></string-name>, <string-name><surname>Cinciripini</surname><given-names>PM</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Estimating statistical power for event-related potential studies using the late positive potential</article-title>. <source>Psychophysiology</source><year>2020</year>;<volume>57</volume>:<elocation-id>e13482</elocation-id>. <pub-id pub-id-type="doi">10.1111/psyp.13482</pub-id><pub-id pub-id-type="pmid">31608456</pub-id></mixed-citation>
              </ref>
              <ref id="R53">
                <label>53</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Versace</surname><given-names>F</given-names></string-name>, <string-name><surname>Kypriotakis</surname><given-names>G</given-names></string-name>, <string-name><surname>Basen-Engquist</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Heterogeneity in brain reactivity to pleasant and food cues: evidence of sign-tracking in humans</article-title>. <source>Soc Cogn Affect Neurosci</source><year>2016</year>;<volume>11</volume>:<fpage>604</fpage>â<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1093/scan/nsv143</pub-id><pub-id pub-id-type="pmid">26609106</pub-id></mixed-citation>
              </ref>
              <ref id="R54">
                <label>54</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Versace</surname><given-names>F</given-names></string-name>, <string-name><surname>Lam</surname><given-names>CY</given-names></string-name>, <string-name><surname>Engelmann</surname><given-names>JM</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Beyond cue reactivity: blunted brain responses to pleasant stimuli predict long-term smoking abstinence</article-title>. <source>Addict Biol</source><year>2012</year>;<volume>17</volume>:<fpage>991</fpage>â<lpage>1000</lpage>. <pub-id pub-id-type="doi">10.1111/j.1369-1600.2011.00372.x</pub-id><pub-id pub-id-type="pmid">21967530</pub-id></mixed-citation>
              </ref>
              <ref id="R55">
                <label>55</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Versace</surname><given-names>F</given-names></string-name>, <string-name><surname>Stevens</surname><given-names>EM</given-names></string-name>, <string-name><surname>Robinson</surname><given-names>JD</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Brain responses to cigarette-related and emotional images in Smokers during smoking cessation: no effect of Varenicline or bupropion on the late positive potential</article-title>. <source>Nicotine Tob Res</source><year>2019</year>;<volume>21</volume>:<fpage>234</fpage>â<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1093/ntr/ntx264</pub-id><pub-id pub-id-type="pmid">29220524</pub-id></mixed-citation>
              </ref>
              <ref id="R56">
                <label>56</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Versace</surname><given-names>F</given-names></string-name>, <string-name><surname>Frank</surname><given-names>DW</given-names></string-name>, <string-name><surname>Stevens</surname><given-names>EM</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The reality of "food Porn": larger brain responses to food-related cues than to erotic images predict cue-induced eating</article-title>. <source>Psychophysiology</source><year>2019</year>;<volume>56</volume>:<elocation-id>e13309</elocation-id>. <pub-id pub-id-type="doi">10.1111/psyp.13309</pub-id><pub-id pub-id-type="pmid">30556253</pub-id></mixed-citation>
              </ref>
              <ref id="R57">
                <label>57</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cuthbert</surname><given-names>BN</given-names></string-name>, <string-name><surname>Schupp</surname><given-names>HT</given-names></string-name>, <string-name><surname>Bradley</surname><given-names>MM</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Brain potentials in affective picture processing: Covariation with autonomic arousal and affective report</article-title>. <source>Biol Psychol</source><year>2000</year>;<volume>52</volume>:<fpage>95</fpage>â<lpage>111</lpage>. <pub-id pub-id-type="doi">10.1016/s0301-0511(99)00044-7</pub-id><pub-id pub-id-type="pmid">10699350</pub-id></mixed-citation>
              </ref>
              <ref id="R58">
                <label>58</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Weinberg</surname><given-names>A</given-names></string-name>, <string-name><surname>Hajcak</surname><given-names>G</given-names></string-name></person-group>. <comment>n.d.</comment><article-title>Beyond good and evil: the time-course of neural activity elicited by specific picture content</article-title>. <source>Emotion</source>;<volume>10</volume>:<fpage>767</fpage>â<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1037/a0020242</pub-id></mixed-citation>
              </ref>
              <ref id="R59">
                <label>59</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Luck</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Gaspelin</surname><given-names>N</given-names></string-name></person-group>. <article-title>How to get statistically significant effects in any ERP experiment (and why you shouldn't)</article-title>. <source>Psychophysiol</source><year>2017</year>;<volume>54</volume>:<fpage>146</fpage>â<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1111/psyp.12639</pub-id></mixed-citation>
              </ref>
              <ref id="R60">
                <label>60</label>
                <mixed-citation publication-type="book"><person-group person-group-type="author"><collab>R Development Core Team</collab></person-group>. <source>A language and environment for statistical computing</source>. <publisher-loc>Vienna, Austria</publisher-loc>: <publisher-name>R Foundation for Statistical Computing</publisher-name>, <year>2020</year>.</mixed-citation>
              </ref>
              <ref id="R61">
                <label>61</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mills</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Wu</surname><given-names>P</given-names></string-name>, <string-name><surname>Lockhart</surname><given-names>I</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Comparisons of high-dose and combination nicotine replacement therapy, Varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis</article-title>. <source>Ann Med</source><year>2012</year>;<volume>44</volume>:<fpage>588</fpage>â<lpage>97</lpage>. <pub-id pub-id-type="doi">10.3109/07853890.2012.705016</pub-id><pub-id pub-id-type="pmid">22860882</pub-id></mixed-citation>
              </ref>
              <ref id="R62">
                <label>62</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kmetova</surname><given-names>A</given-names></string-name>, <string-name><surname>Kralikova</surname><given-names>E</given-names></string-name>, <string-name><surname>Stepankova</surname><given-names>L</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Factors associated with weight changes in successful Quitters participating in a smoking cessation program</article-title>. <source>Addict Behav</source><year>2014</year>;<volume>39</volume>:<fpage>239</fpage>â<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/j.addbeh.2013.10.010</pub-id><pub-id pub-id-type="pmid">24140303</pub-id></mixed-citation>
              </ref>
              <ref id="R63">
                <label>63</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Prodâhom</surname><given-names>S</given-names></string-name>, <string-name><surname>Locatelli</surname><given-names>I</given-names></string-name>, <string-name><surname>Giraudon</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Predictors of weight change in sedentary Smokers receiving a standard smoking cessation intervention</article-title>. <source>Nicotine Tob Res</source><year>2013</year>;<volume>15</volume>:<fpage>910</fpage>â<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1093/ntr/nts217</pub-id><pub-id pub-id-type="pmid">23048177</pub-id></mixed-citation>
              </ref>
              <ref id="R64">
                <label>64</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ben Taleb</surname><given-names>Z</given-names></string-name>, <string-name><surname>Ward</surname><given-names>KD</given-names></string-name>, <string-name><surname>Asfar</surname><given-names>T</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Smoking cessation and changes in body mass index: findings from the first randomized cessation trial in a low-income country setting</article-title>. <source>Nicotine Tob Res</source><year>2017</year>;<volume>19</volume>:<fpage>351</fpage>â<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1093/ntr/ntw223</pub-id><pub-id pub-id-type="pmid">27613912</pub-id></mixed-citation>
              </ref>
              <ref id="R65">
                <label>65</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Krukowski</surname><given-names>RA</given-names></string-name>, <string-name><surname>Bursac</surname><given-names>Z</given-names></string-name>, <string-name><surname>Little</surname><given-names>MA</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>The relationship between body mass index and post-cessation weight gain in the year after quitting smoking: A cross-sectional study</article-title>. <source>PLoS One</source><year>2016</year>;<volume>11</volume>:<elocation-id>e0151290</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0151290</pub-id><pub-id pub-id-type="pmid">26977598</pub-id></mixed-citation>
              </ref>
              <ref id="R66">
                <label>66</label>
                <mixed-citation publication-type="other"><person-group person-group-type="author"><string-name><surname>McElreath</surname><given-names>R</given-names></string-name></person-group>. <article-title>Statistical Rethinking: a Bayesian course with examples in R and Stan</article-title>. <year>2016</year>.</mixed-citation>
              </ref>
              <ref id="R67">
                <label>67</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>HPBD</collab></person-group>. <article-title>Boca Raton</article-title>. <source>J R Stat Soc Ser A Stat Soc</source><year>2015</year>;<volume>178</volume>:<elocation-id>301</elocation-id>. <pub-id pub-id-type="doi">10.1111/j.1467-985X.2014.12096_1.x</pub-id></mixed-citation>
              </ref>
              <ref id="R68">
                <label>68</label>
                <mixed-citation publication-type="other"><person-group person-group-type="author"><collab>Stan Development</collab></person-group>. <article-title>Rstan: the R interface to Stan. R package version 2192</article-title>. <year>2019</year>.</mixed-citation>
              </ref>
              <ref id="R69">
                <label>69</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>BÃ¼rkner</surname><given-names>P-C</given-names></string-name></person-group>. <article-title>Brms: an R package for Bayesian Multilevel models using Stan</article-title>. <source>J Stat Softw</source><year>2017</year>;<volume>80</volume>:<fpage>1</fpage>â<lpage>28</lpage>. <pub-id pub-id-type="doi">10.18637/jss.v080.i01</pub-id></mixed-citation>
              </ref>
              <ref id="R70">
                <label>70</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Berry</surname><given-names>DA</given-names></string-name></person-group>. <article-title>Bayesian clinical trials</article-title>. <source>Nat Rev Drug Discov</source><year>2006</year>;<volume>5</volume>:<fpage>27</fpage>â<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1038/nrd1927</pub-id><pub-id pub-id-type="pmid">16485344</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
